The U.S. health department permanently filled four key leadership roles at the Food and Drug Administration, formalizing the directors for drug and vaccine review centers following the nomination of Heidi Overton to head the agency. The appointments include Michael Davis leading the Center for Drug Evaluation and Research and Karim Mikhail leading the Center for Biologics Evaluation and Research.
Over the past year, the regulatory body has experienced the exit of more than 3,000 personnel, creating institutional strain across its core divisions.
In Plain English: The Clinical Takeaway
- Stable Drug Regulation: The permanent appointment of Michael Davis to direct the Center for Drug Evaluation and Research ensures continuous oversight for prescription medication approvals and safety monitoring.
- Vaccine and Biologics Continuity: Karim Mikhail steps in permanently to direct the Center for Biologics Evaluation and Research, maintaining review pathways for vaccines, blood products, and advanced cellular therapies.
- Technology Integration: The creation of a dedicated deputy commissioner role for technology and artificial intelligence highlights an ongoing shift toward automated data review processes within federal health oversight.
Leadership Restructuring at Core Regulatory Centers
According to federal announcements reported by Reuters, the Department of Health and Human Services formalized leadership changes by naming acting officials to permanent posts. Michael Davis, a psychiatrist who served as the Center for Drug Evaluation and Research deputy director before taking over as acting director in May, will now lead the division permanently. Karim Mikhail, a former Merck official who previously advised the agency, assumes the permanent directorship of the Center for Biologics Evaluation and Research.
These two divisions form the backbone of American medical regulation, evaluating clinical trial data, manufacturing quality controls, and post-market safety signals for therapeutics and immunizations. The permanent appointments arrive as the agency navigates a challenging regulatory landscape marked by intense public scrutiny over vaccine approvals, drug access, and public health communications.
Alongside the drug and vaccine units, Bret Koplow—an attorney at the agency since 2011 who served in an acting capacity—was named permanent director of the Center for Tobacco Products. Meanwhile, Jared Seehafer was appointed as the agency’s first deputy commissioner for technology and artificial intelligence. Seehafer joined the agency as an adviser after founding a life science software company and working in biotech investment advising, aligning with the administration’s push to integrate artificial intelligence into federal review workflows.
Institutional Context and Public Health Impact
The Food and Drug Administration has faced severe headwinds over the past year, losing thousands of staff members across various divisions, including key division heads.
| Appointee | Permanent Role | Background & Prior Status |
|---|---|---|
| Michael Davis | Director, Center for Drug Evaluation and Research (CDER) | Psychiatrist; served as CDER deputy director before taking over as acting director in May. |
| Karim Mikhail | Director, Center for Biologics Evaluation and Research (CBER) | Former Merck official; previously advised the FDA before serving as acting director. |
| Bret Koplow | Director, Center for Tobacco Products (CTP) | Attorney at the FDA since 2011; served previously in an acting capacity. |
| Jared Seehafer | Deputy Commissioner for Technology and Artificial Intelligence | Joined as an adviser in 2025 after founding a life science software company and biotech investing background. |
Contraindications & When to Consult a Doctor
Patients should never alter, pause, or discontinue prescribed therapeutic regimens based on regulatory news updates.
Consult a qualified healthcare professional immediately if you experience adverse drug reactions, unexpected side effects, or symptoms of an allergic reaction—such as urticaria (hives), dyspnoea (shortness of breath), or angioedema (swelling of the face, lips, or tongue). Always review your complete medical history, including known allergies and concurrent pharmacological treatments, with your prescribing physician or clinical pharmacist.
Looking Ahead: Navigating Regulatory Stability
References
- U.S. Food and Drug Administration (FDA) Leadership Announcements. Reuters coverage.
- Center for Drug Evaluation and Research (CDER) Regulatory Framework.
- Center for Biologics Evaluation and Research (CBER) Standards.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, legal counsel, or official regulatory guidance.
Keep reading
